|
|
|
| Application Value of Serum AFP AFU CEA and CA19-9 in the Diagnosis of Gastric Cancer |
| SU Xiaolan, LONG Xiangyu, WANG Ying, et al |
| West China Guang'an Hospital of Sichuan University, Sichuan Guang'an 638000, China |
|
|
|
|
Abstract Objective: To investigate the application value of serum alpha-fetoprotein (AFP), α-L-fucosidase (AFU), carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in the diagnosis of gastric cancer (GC), and provide references for early diagnosis of GC. Methods: 50 patients with GC admitted to the hospital between January 2018 and January 2019 were included in GC group. 50 patients with benign gastric lesions admitted during the same period were selected as the control group. The expression levels of serum AFP, AFU, CEA and CA19-9 were compared between the two groups. The expression levels in patients with GC and different clinical features were analyzed. Results: The expression levels of AFP, AFU, CEA and CA19-9 in GC group were significantly higher than those in the control group (P<0.05). ROC curve analysis indicated that the areas under the curves of serum AFP, AFU, CEA and CA19-9 and the combination of the four for detection of GC were 0.935, 0.943, 0.931, 0.996 and 0.998, respectively. The sensitivity, specificity and yoden index of AFP, AFU, CEA and CA19-9 combined detection were higher than those of other independent detection. Levels of AFP, AFU, CEA and CA19-9 in patients with GC decreased significantly with the increase of differentiation degree, and the levels in patients with lymph node metastasis were significantly higher than those without (all P<0.05). The combined detection of AFP, AFU, CEA and CA19-9 in the diagnosis of GC patients' differentiation, the area under the curve of lymph node metastasis, the specificity and the yoden index were higher than those detected separately. Conclusion: The levels of serum AFP, AFU, CEA and CA19-9 are high in patients with GC. The combined detection of AFP, AFU, CEA and CA19-9 can improve the diagnostic efficiency of GC and its progression.
|
|
|
|
|
|
[1] Holly A Martinson, Nancy J Shelby, Steven R Alberts,et al. Gastric cancer in Alaska native people: a cancer health disparity[J]. World Journal of Gastroenterology, 2018, 24(25):2722~2732.
[2] 秦娟,晏伟,王三喜,等.Ki67、p53及EGFR在胃癌组织中的表达水平及临床意义[J].实用癌症杂志,2017,32(1):37~39.
[3] 高毅.沙利度胺联合IRIS方案二线治疗晚期胃癌的疗效与安全性分析[D].郑州大学,2017.
[4] 田春琴,蒋冬梅,崔立春,等.血清肿瘤标志物及免疫组化指标在不同临床病理特征胃腺癌患者中的表达水平[J].癌症进展,2017,16(9):96~98,105.
[5] 李三清,李永强,周凌云,等.联合应用CA19-9、CEA和AFP对胃癌的诊断价值评价[J].检验医学与临床,2016,13(A02):105~107.
[6] 韩笑,张喜平,魏子妤.甲胎蛋白、α-L-岩藻糖苷酶、糖类抗原199在原发性肝癌早期筛查中的作用[J].内蒙古医科大学学报,2017,39(2):36~39.
[7] 中华人民共和国国家卫生和计划生育委员会.胃癌规范化诊疗指南(试行)[J].慢性病学杂志,2013,5(10):47~51.
[8] 侯洁心,郭萍.免疫组化标志物Her-2和肿瘤标志物在胃癌诊断中的价值分析[J].陕西医学杂志,2019,48(1):121~124.
[9] 王玎,董召刚,王立水,等.血清癌胚抗原和CA19-9对胃间质瘤的临床价值[J].中华检验医学杂志,2019,42(2):128~134.
[10] 鹿存芝,李向阳.甲胎蛋白联合CA199、AFU及CEA在原发性肝癌中的诊断价值[J].检验医学与临床,2017,14(10):1412~1414.
[11] 翁艳,褚云香,王东盛,等.CEA、CA125、CA19-9对胃癌的诊断价值及与TNM分期、淋巴结转移的关系[J].癌症进展,2019,17(5):582~584. |
|
|
|
2020, Vol. 26 
